BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 أكتوبر 2023 07:00:41 بحسب Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 سبتمبر 2023 07:00:46 بحسب Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

23 أغسطس 2023 16:01:54 بحسب Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 أغسطس 2023 16:01:28 بحسب Nasdaq GlobeNewswire

BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update

03 أغسطس 2023 07:00:58 بحسب Nasdaq GlobeNewswire

BioCryst to Report Second Quarter 2023 Financial Results on August 3

20 يوليو 2023 07:00:37 بحسب Nasdaq GlobeNewswire

BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey

19 يوليو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

BioCryst to Participate in the 2023 US HAEA National Summit

17 يوليو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 يوليو 2023 07:00:12 بحسب Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 يونيو 2023 07:00:42 بحسب Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conference

01 يونيو 2023 07:00:45 بحسب Nasdaq GlobeNewswire

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress

31 مايو 2023 07:02:04 بحسب Nasdaq GlobeNewswire

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile

22 مايو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 مايو 2023 16:01:01 بحسب Nasdaq GlobeNewswire

BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update

03 مايو 2023 07:00:55 بحسب Nasdaq GlobeNewswire

BioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat)

27 أبريل 2023 07:00:01 بحسب Nasdaq GlobeNewswire

BioCryst to Report First Quarter 2023 Financial Results on May 3

19 أبريل 2023 07:00:27 بحسب Nasdaq GlobeNewswire

BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon

18 أبريل 2023 07:00:00 بحسب Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

12 أبريل 2023 07:00:00 بحسب Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 أبريل 2023 07:00:36 بحسب Nasdaq GlobeNewswire